USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ALTOR BIOSCIENCE CORPORATION
Address: 2810 N COMMERCE PKY
MIRAMAR, FL 33025-3958
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $951,616.00 4
SBIR Phase II $3,187,074.00 1

Award List:

Novel IL-15 Superagonist Therapy for Bladder Cancer

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hing C. Wong – 954-443-8600
Award Amount: $225,279.00
Abstract:
DESCRIPTION (provided by applicant): Non-Muscle Invasive Bladder cancer (NMIBC), the fifth most common cancer in the United States and the costliest to treat per patient of all cancers, tends to recur, requiring repeated intervention and long-term follow-up. NMIBC are usually treated by surgical… More

Tissue Factor Antagonists for ALI/ARDS

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Hing C. Wong – 954-443-8600
Award Amount: $3,187,074.00
Abstract:
DESCRIPTION (provided by applicant): The pathogenesis of ALI/ARDS involves both procoagulant and inflammatory mechanisms. Extravascular fibrin deposition in the lung is a characteristic pathologic feature of ALI/ARDS and intra-alveolar thrombi develop inthe lungs of patients with ALI/ARDS. Tissue… More

Evaluating Relevant Vaccine Epitopes Displayed on HIV-Infected Cells

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hing C. Wong – 954-443-8600
Award Amount: $237,181.00
Abstract:
DESCRIPTION (provided by applicant): The HIV/AIDS pandemic continues to wreak havoc on global scale and has become one of the most destructive pandemics in recorded history. Despite the tremendous improvements in life-extending antiretroviral therapy, it is likely that the only way by which the… More

IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hing C. Wong – 954-443-8600
Award Amount: $231,853.00
Abstract:
DESCRIPTION (provided by applicant): Multiple myeloma (MM) is the second most commonly diagnosed hematologic malignancy with an estimated 20,520 newly diagnosed cases and 10,610 deaths due to MM in the United States in 2011. MM is a disease of the elderlywith a median age at diagnosis of 70 years… More

CD20-targeted IL-15 immunotherapeutic for B-cell malignancies

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hing C. Wong – 954-443-8600
Award Amount: $257,303.00
Abstract:
DESCRIPTION (provided by applicant): Non-Hodgkin lymphoma (NHL) represents a significant clinical challenge in cancer management. Approximately 70,000 new cases of NHL are diagnosed annually in the U.S. and NHL ranks fifth in cancer incidence and mortality. The majority of NHL cases are of B-cell… More